Niopeg

Class [005]
Pharmaceuticals for decreasing the incidence of infection; Pharmaceuticals for treating infection; Pharmaceuticals for treating cancer; Pharmaceuticals for white blood cell production; Pharmaceuticals for treating patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs; Pharmaceutical preparations for the treatment of patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs; Pharmaceutical preparations for stimulating white blood cell production; Pharmaceutical and biological preparations for medical use, namely, by subcutaneous administration; Pegfilgrastim biosimilar for pharmaceutical purposes; Pharmaceutical preparations namely, pharmaceuticals used for stimulating white blood cell production; Cancer pharmaceuticals; Biosimilar pharmaceuticals; Pharmaceutical preparations for hemopoietic growth factors; pharmaceutical preparations, namely recombinant-human granulocyte-CSF for use in stimulating white blood cell production; Pharmaceutical preparations used for stimulating white blood cell production for the treatment of neutropenia, hematopoietic syndrome;